Navigation Links
Hemostemix Announces US Patent Allowance
Date:6/5/2013

Kyriat Weizmann, Israel (PRWEB) June 05, 2013

Hemostemix, Ltd. (“Hemostemix”, the “Company”) announced today the issuance of a Notice of Allowance from the United States Patent and Trademark Office for a patent entitled “A Composition Comprising A Progenitor/Precursor Cell Population”.

The patent pertains to a population of cultured cells which meet certain criteria and constitute the foundation of the Company’s angiogenic (blood vessel growing) technology. The product developed on the basis of this technological platform will be used in a Phase 2 clinical trial for critical limb ischemia. The trial protocol was recently cleared by Health Canada and the trial is expected to commence later this year.

This patent is part of a broad technology platform now protected by 38 patents issued in major markets, such as the US, EU, Japan and China. The company continues to aggressively file and prosecute patents around all aspects of its technology as an important foundation for its global commercialization plans.

“The cell population which is the subject of this patent,” stated Hemostemix’ President, Dr. Valentin Fulga, “is an important pillar of our technology. This cell population is generated from a core population of cells we named Synergetic Cell Population (“SCP”), which is isolated from a simple blood collection. We believe the SCP not only has the potential to differentiate into blood vessels, but can also be transformed, through proprietary cell-culturing techniques, into other cell types, such as cardiomyocyte-like cells and neural cells.”

About Hemostemix Ltd

Hemostemix Ltd is a company incorporated in Israel with an operating research, development and manufacturing facility in Kiryat Weizmann Science Park, Ness Ziona. Hemostemix and Kwalata Trading Ltd (“Kwalata”), registered in Cyprus, are wholly-owned subsidiaries of Canadian-based parent company, Theravitae Inc (“TVI”) (together the “Hemostemix Group”). Kwalata holds the intellectual property on behalf of the Hemostemix Group. On 14 May 2013, TVI announced a letter of intent signed with Technical Ventures RX Corp (TSX-V:TIK.P) ("Technical") regarding a proposed Qualifying Transaction in which Technical would acquire TVI and its subsidiaries in a share transaction. For more information see http://www.hemostemix.com.

Read the full story at http://www.prweb.com/releases/2013Hemostemix/USPTOallowance/prweb10777870.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. The Hemostemix Group of Companies Provides Corporate Strategy Update
2. Array BioPharma Announces Pricing of Public Offering of $115 Million of Convertible Senior Notes
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Arteriocyte announces Launch of Compass Biomedical
5. TNI BioTech, Inc. Announces Death of Senior Vice President and Chief Medical Officer, Dr. Ronald Herberman
6. Elsevier Announces its Collaboration with Kasetsart University, Thailand
7. Celsion Corporation Announces $9.83 Million Registered Direct Offering
8. Caris Life Sciences Announces Planned Expansion of Next-Generation Sequencing (NGS) Capabilities
9. 3SBio Inc. Announces Completion of Merger
10. AtheroNova Announces Shipment of Phase 1 Drug Product
11. The Sidney Kimmel Foundation for Cancer Research Announces 2013 Grant Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... CA (PRWEB) , ... November 30, 2016 , ... ... a new moving magnet Voice Coil Actuator with a flexure design that ensures ... long life with cost-effective pricing and is ideally suited where extreme precision is ...
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
(Date:11/30/2016)... 2016 Part of 5m$ Investment in ... ... Aptuit, LLC today announced that it had successfully completed the ... compounds have increased the Screening Collection to over 400,000. The ... capabilities of the company. This expansion, complemented by new robotics ...
(Date:11/30/2016)... ... November 30, 2016 , ... On 28 November 2016, the International Union of ... nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively for element 113, 115, ... proposed by the discoverers have been approved by the IUPAC Bureau. The IUPAC Council ...
Breaking Biology Technology:
(Date:11/16/2016)... , Nov. 16, 2016 Sensory ... experience and security for consumer electronics, and ... financial and retail industry, today announced a global ... convenient way to authenticate users of mobile banking ... TrulySecure™ software which requires no specialized ...
(Date:11/14/2016)... Nov. 14, 2016  xG Technology, Inc. ("xG" or ... critical wireless communications for use in challenging operating environments, ... 30, 2016. Management will hold a conference call to ... p.m. Eastern Time (details below). Key Recent ... $16 million binding agreement to acquire Vislink Communication Systems. ...
(Date:6/22/2016)... June 22, 2016  The American College of Medical Genetics ... Executive Magazine as one of the fastest-growing trade shows ... at the Bellagio in Las Vegas . ... percentage of growth in each of the following categories: net ... and number of attendees. The 2015 ACMG Annual Meeting was ...
Breaking Biology News(10 mins):